Abstract
Mammary derived growth inhibitor (MDGI) is a member of the family of cytoplasmic fatty acid binding proteins (FABPs), which bind hydrophobic ligands such as fatty acids, retinoids, eicosanoids and prostaglandines. MDGI and an 11 amino acid MDGI-derived conserved C-terminal peptide (P108) inhibits growth of normal mammary epithelial cells in tissue and organ culture, but fails to inhibit proliferation of many breast cancer cell lines in vitro. Here, the effects of peptide P108 on tumor growth of MCF-7, MDA-MB468 and MDA-MB231 human breast cancer cell lines in nude mice were tested. To deliver P108 into tumors, a novel peptide production system was applied for expression and secretion of small bioactive peptides in mammalian cells. Functional differentiation was observed in MCF-7 and MDA-MB468 cells upon P108 expression. In addition, EGF-dependent colony formation in soft agar by MDA-MB468 cells was inhibited by secreted P108. Tumor growth in athymic nude mice was suppressed in all three cell lines tested. Furthermore, P108 expressed by MCF-7/P108 cells caused paracrine tumor growth inhibition of MDA-MB231 cells. These results indicate that breast cancer inhibition by P108 is independent of binding to hydrophobic ligands and is perhaps mediated by interference with EGF-dependent signaling pathways.
Similar content being viewed by others
References
Billich S, Wissel T, Kratzin H, Hahn U, Hegenhoff B, Lezius AG and Spener F . 1988 Eur J Biochem 175: 549–556
Boehmer F-D, Kraft R, Otto A, Wernstedt C, Hellman U, Kurtz A, Muller T, Rohde K, Etzold G, Lehmann W, Langen P, Heldin C-H and Grosse R . 1987 J Biol Chem 262: 15137–15143
Boehmer F-D, Mieth M, Reichmann G, Taube C, Grosse R and Hollenberg MD . 1988 J Cell Biochem 38: 199–204
Brakch N, Galanopoulou AS, Patel YC, Boileau G and Seidah NG . 1995 FEBS Lett 362: 143–146
Brandt R and Grosse R . 1992 Biochem Biophys Res Commun 189: 406–413
Brandt R and Ebert AD . 1998 Prog Molec Subcell Biol 20: 197–248
Ennis BW, Valverius EM, Bates SE, Lippman ME, Bellot F, Kris R, Schlessinger J, Masui H, Goldenberg A and Mendelsohn J . 1989 Mol Endocrinol 3: 1830–1838
Ervin PR, Kaminski MS, Cody RL and Wicha MS . 1989 Science 244: 1585–1587
Glatz JF, van Nieuwenhoven FA, Liuken JJ, Schaap FG and van der Vusse GJ . 1997 Prostaglandins Leukot Essent Fatty Acids 57: 373–378
Grosse R, Boehmer F-D, Binas B, Kurtz A, Spitzer E, Muller T and Zschiesche W . 1992 Cancer Treat Res 61: 69–96
Huynh HT, Larsson C, Narod S and Pollak N . 1995 Cancer Res 5585: 2225–2231
Huynh HT, Alpert L and Pollak N . 1996 Cancer Res 56: 4865–4870
Kurtz A, Vogel F, Funa K, Heldin C-H and Grosse R . 1990 J Cell Biol 110: 1779–1789
Kurtz A, Spitzer E, Zschiesche W, Wellstein A and Grosse R . 1997 Bioch Soc Symp 69: 51–59
Lassen D, Lucke C, Kveder M, Mesgarzadeh A, Schmidt JM, Specht B, Lezius A, Spener F and Ruterjans H . 1995 Eur J Biochem 230: 266–280
Lehmann W, Widmaier R and Langen P . 1989 Biomedica Biochimica Acta 48: 143–151
Liu XH, Connolly JM and Rose DP . 1996 Clin Exp Metastasis 14: 145–152
Natarajan R and Nadler J . 1998 Front Biosci 3: 81–88
Peles E, Bacus SS, Koski RA, Lu HS, Wen D, Ogden SG, Levy RB and Yarden Y . 1992 Cell 69: 205–216
Phelan CM, Larsson C, Baird S, Futreal PA, Ruttledge MH, Morgan K, Tonin P, Hung H, Korneluk RG, Pollak MN and Narod SA . 1996 [published erratum appears in Genomics 1996 Sep 1; 36377] Genomics 34: 63–68
Rytomaa T and Toivonen H . 1979 Mechan Ageing Dev 9: 471–480
Silberstein G and Daniel C . 1987 Science 37: 291–293
Steiner DF, Smeekens SP, Ohagi S and Chan SJ . 1992 J Biol Chem 267: 23435–23438
Treuner M, Kozak C, Gallhan C, Spitzer E, Grosse R and Muller T . 1994 Gene 147: 237–242
Verkamp J, Peeters R and Maatman R . 1991 Biochem Biophys Acta 1081: 1–24
Veerkamp JH, Smith GH, Salomon DS and Grosse R . 1995 J Cell Biol 127: 1097–1109
Wallukat G, Boehmer F-D, Engstrom U, Langen P, Hollenberg MD, Behlke J, Kuehn H and Grosse R . 1991 Mol Cell Biochem 102: 49–60
Yang Y, Spitzer E, Kenney N, Zschiesche E, Li M, Kromminga A, Muller T, Spener F, Lezius A, Veerkamp JH, Smith GH, Salomon DS and Grosse R . 1995 J Cell Biol 127: 1097–1109
Zschiesche W, Kleine AH, Spitzer E, Veerkamp JH and Glatz JF . 1995 Histochem Cell Biol 103: 147–156
Acknowledgements
We thank Dr Dennis Shields for providing a cDNA for pre-prosomatostatin and antibody to the pre-pro-protein. We thank Dr David Salomon for giving us the β-casein antibody. We are very grateful to Dr Anton Wellstein and Dr Anna Tate-Riegel for providing conceptual input on the peptide delivery construct and for their continuous support and helpful discussions. We also wish to thank Dr Richard Grosse for his support of the project and critical reading of the manuscript.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wang, HL., Kurtz, A. Breast cancer growth inhibition by delivery of the MDGI-derived peptide P108. Oncogene 19, 2455–2460 (2000). https://doi.org/10.1038/sj.onc.1203575
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1203575
- Springer Nature Limited
Keywords
This article is cited by
-
Sensitization of lung cancer cells to cisplatin by β-elemene is mediated through blockade of cell cycle progression: antitumor efficacies of β-elemene and its synthetic analogs
Medical Oncology (2013)
-
Mammary-derived growth inhibitor (MDGI) interacts with integrin α-subunits and suppresses integrin activity and invasion
Oncogene (2010)
-
CRBP suppresses breast cancer cell survival and anchorage-independent growth
Oncogene (2001)